Trial Profile

A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 986207 (Primary) ; COM 701 (Primary) ; Nivolumab (Primary)
Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Head and neck cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions; Pharmacokinetics
Sponsors Compugen

18 Jul 2024 Status changed from active, no longer recruiting to completed.
10 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 Aug 2024.
10 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 May 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com